Agenus reported long-term survival for more than 50% of patients treated with its drug combination, supporting its promise. The combination is still being studied, so the report does not prove it works better than another option.
This survival signal gives Agenus more support for its lead drug combination in a hard-to-treat cancer. The study is still ongoing, and the report does not prove the treatment works better than another option.
Follow Agenus (AGEN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AGEN